Recombinant porcine coagulation factor VIII (B-domain deleted) ( DrugBank: Factor VIII )


1 disease
IDDisease name (Link within this page)Number of trials
288Autoimmune acquired coagulation factor deficiency1

288. Autoimmune acquired coagulation factor deficiency


Clinical trials : 205 Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-000181-34-GB
(EUCTR)
29/06/201123/06/2011Study of a new factor VIII replacement for patients with acquired hemophilia AEfficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Acquired Haemophilia A
MedDRA version: 14.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: OBI-1
Product Code: OBI-1
INN or Proposed INN: obyoctocog alfa
Other descriptive name: recombinant porcine coagulation factor VIII (B-domain deleted)
Baxter Innovations GmbHNULLNot RecruitingFemale: yes
Male: yes
28United States;Hungary;Canada;Germany;Italy;United Kingdom;Sweden;India